Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002754 | 0.87 | KDM4E (0.46) | QPCTKDM4EHPGDSRCGRIN2D | |
| SCHEMBL24392618 | 0.83 | KDM4E (0.43) | QPCTKDM4EHPGDSRCGRIN2D | |
| SCHEMBL16432412 | 0.83 | GRIN2D (0.51) | KDM4EHPGDMTNR1AMTNR1BSRC | |
| SCHEMBL4565100 | 0.81 | BCL2 (0.44) | QPCTKDM4EHPGDAPEX1SRC | |
| Hydrochloric Acid SCHEMBL28068007 | 0.81 | GRIN2D (0.50) | KDM4EHPGDMTNR1AMTNR1BSRC | |
| SCHEMBL14699028 | 0.81 | SRC (0.40) | QPCTCYP1A2KDM4ECYP2D6CYP3A4 | |
| Bromide SCHEMBL2051879 | 0.80 | BCL2 (0.43) | QPCTKDM4EHPGDAPEX1SRC | |
| SCHEMBL202254 | 0.80 | TNFSF11 (0.50) | QPCTKDM4EHSD17B10HPGDMTNR1A | |
| SCHEMBL4430431 | 0.80 | TNFSF11 (0.50) | QPCTKDM4EHSD17B10HPGDMTNR1A | |
| SCHEMBL30822504 | 0.79 | GRIN2D (0.51) | KDM4EHPGDMTNR1AMTNR1BSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| EP-2501233-A1 | QUINAZOLINE COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| EP-2155656-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | Cipla Limited (IN) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008125867-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | CIPLA LIMITED (IN) | 2008-10-23 | — | — | WO | disclosed |
| EP-1904458-A1 | METHOD FOR THE PRODUCTION OF QUINAZOLINONE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003486-A1 | METHOD FOR THE PRODUCTION OF QUINAZOLINONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137586-A1 | Process for the Preparation of Gefitinib | EGFR, BRAF, KRAS | QPCT 782/4885CYP1A2 304/4885KDM4E 1987/4885 |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | QPCT 691/4885CYP1A2 181/4885KDM4E 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.